Study of Nesiritide in Diastolic Heart Failure.

This study has been completed.
Scios, Inc.
Information provided by (Responsible Party):
Marc Semigran, Massachusetts General Hospital Identifier:
First received: March 30, 2006
Last updated: March 24, 2014
Last verified: March 2014
We hypothesize that nesiritide will have favorable effect in decreasing heart filling pressures and echocardiogram studies.

Condition Intervention Phase
Diastolic Heart Failure
Drug: neseritide
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure.

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Estimated Enrollment: 20
Study Start Date: December 2002
Study Completion Date: December 2003
Primary Completion Date: December 2003 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: neseritide
    Other Name: BNP
Detailed Description:

In previous studies, patients with systolic heart failure were given nesiritide and had reduced heart filling pressures. The FDA has approved nesiritide for these patients.

Between one-third and one-half of patients with heart failure have diastolic heart failure. Few of these patients have been studied while receiving nesiritide.

A study is needed to test nesiritide on this specific type of heart failure.

Patients will undergo a heart catheterization and heart biopsy. Patients will then be transferred to the intensive care unit for monitoring. An echocardiogram will be obtained, followed by an infusion of nesiritide for 24 hours. At the completion of the infusion, a repeat echocardiogram will be obtained.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Elevated heart filling pressure. Ejection fraction >45%. Blood pressure >90. Physician feels that the patient needs intravenous medication for heart failure.

Exclusion Criteria:

Patients receiving intravenous medication. Patients with significant heart disease or who are unstable. Patients with kidney failure or severe heart valve disease.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00309868

Sponsors and Collaborators
Massachusetts General Hospital
Scios, Inc.
Principal Investigator: Marc J S, MD Massachusetts General Hospital
  More Information

Responsible Party: Marc Semigran, Medical Director , Heart Failure and Cardiac Transplantation, Massachusetts General Hospital Identifier: NCT00309868     History of Changes
Other Study ID Numbers: 2002-p-001736 
Study First Received: March 30, 2006
Last Updated: March 24, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Massachusetts General Hospital:
heart catheterization

Additional relevant MeSH terms:
Heart Failure
Heart Failure, Diastolic
Cardiovascular Diseases
Heart Diseases
Natriuretic Peptide, Brain
Cardiovascular Agents
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on May 02, 2016